Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for tenapanor to control serum phosphorus in adult...

July 30, 2021

Executive Moves

EyeGate Pharma names Brian Strem as president and CEO

EyeGate Pharmaceuticals (NASDAQ:EYEG) appointed Brian Strem, Ph.D., as president, CEO and a director, effective immediately. He replaces acting CEO, Franz Obermayr, Ph.D., who reassumes his position as EVP clinical...

July 28, 2021

Developments

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...

July 28, 2021

Developments

Talkiatry completes $20-million Series A funding

Closely-held Talkiatry, a provider of accessible in-network psychiatric care, completed its $20-million a Series A funding, of which $15-million was led by Left Lane Capital, with participation from Dr. Richard Park...

July 28, 2021

Developments

FDA clears Asensus Surgical 510(k) for articulating instruments

Asensus Surgical (NYSE American:ASXC) received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System robotic technology platform. Articulating instruments offer better...

July 28, 2021

Markets

Cantor starts Nyxoah at OW; PT $43

Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price target of $43, citing the company’s “pipeline and uniquely differentiated product”. The stock closed at $32...

July 28, 2021

Markets

Canaccord starts CVRx at buy; PT $30

Canaccord Genuity initiated coverage of CVRx (NASDAQ:CVRX) with a “buy” rating and price target of $30. The stock closed at $20.22 on July 23. “We believe that CVRx is uniquely positioned in addressing significant unmet...

July 26, 2021

Markets

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

July 26, 2021

Developments

Cybin receives conditional listing approval from NYSE American

Cybin (NEO:CYBN; OTCQB:CLXPF) has received conditional listing approval from the NYSE American stock exchange, under the ticker symbol, CYBN. In a statement, Doug Drysdale, CEO of Cybin, said conditional listing...

July 22, 2021

Markets

Cantor starts SELLAS Life Sciences at OW; PT $18

Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...

July 21, 2021

Markets

Stifel starts GH Research at buy; PT $26

Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...

July 20, 2021

Markets

Analysts start Alpha Teknova at outperform, buy

Analysts for William Blair and BTIG initiated coverage of Alpha Teknova (NASDAQ:TKNO) with “outperform” and “buy” ratings, respectively, citing the company’s exposure to several large, rapidly growing markets. “In...

July 20, 2021

Cantor halves Ardelyx PT to $7 from $14; maintains OW rating

EyeGate Pharma names Brian Strem as president and CEO

Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI

Talkiatry completes $20-million Series A funding

FDA clears Asensus Surgical 510(k) for articulating instruments

Cantor starts Nyxoah at OW; PT $43

Canaccord starts CVRx at buy; PT $30

Stifel starts Acumen Pharma at buy; PT $27

Cybin receives conditional listing approval from NYSE American

Cantor starts SELLAS Life Sciences at OW; PT $18

Stifel starts GH Research at buy; PT $26

Analysts start Alpha Teknova at outperform, buy

General

More